Desai A - Search Results

1

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.

Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Schoenfeld JD, et al. Among authors: desai a. JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955. JAMA Oncol. 2020. PMID: 32852531 Free PMC article. Clinical Trial.

2

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.

Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Hanna GJ, et al. Among authors: desai am. Clin Cancer Res. 2022 Feb 1;28(3):468-478. doi: 10.1158/1078-0432.CCR-21-2635. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667025 Free PMC article. Clinical Trial.

3

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A. Buchbinder EI, et al. Among authors: desai a. Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Am J Clin Oncol. 2016. PMID: 26558876 Free PMC article. Review.

4

Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.

Danesh M, Faulkner-Jones B, Desai A, Kim CC. Danesh M, et al. Among authors: desai a. JAMA Dermatol. 2019 Apr 1;155(4):496-497. doi: 10.1001/jamadermatol.2018.5347. JAMA Dermatol. 2019. PMID: 30758504 No abstract available.

5

Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.

Miller DM, Trowbridge RM, Desai A, Drews RE. Miller DM, et al. Among authors: desai a. J Immunother Cancer. 2018 Nov 19;6(1):122. doi: 10.1186/s40425-018-0437-4. J Immunother Cancer. 2018. PMID: 30454071 Free PMC article.

6

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).

Sun J, Gastman BR, McCahon L, Buchbinder EI, Puzanov I, Nanni M, Lewis JM, Carvajal RD, Singh-Kandah S, Desai AM, Raskin L, Nielson CM, Ismail R, Zager JS. Sun J, et al. Melanoma Manag. 2020 Jun 15;7(2):MMT41. doi: 10.2217/mmt-2020-0005. Melanoma Manag. 2020. PMID: 32821373 Free PMC article.

7

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).

Perez MC, Zager JS, Amatruda T, Conry R, Ariyan C, Desai A, Kirkwood JM, Treichel S, Cohan D, Raskin L. Perez MC, et al. Among authors: desai a. Melanoma Manag. 2019 Jul 3;6(2):MMT19. doi: 10.2217/mmt-2019-0012. Melanoma Manag. 2019. PMID: 31406563 Free PMC article.

8

In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies.

Kopp A, Dong S, Kwon H, Wang T, Desai AA, Linderman JJ, Tessier P, Thurber GM. Kopp A, et al. Among authors: desai aa. bioRxiv [Preprint]. 2024 Apr 10:2024.04.06.588433. doi: 10.1101/2024.04.06.588433. bioRxiv. 2024. PMID: 38645231 Free PMC article. Preprint.

9

Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.

Desai A, Khataniar H, Hashash JG, Farraye FA, Regueiro M, Kochhar GS. Desai A, et al. Inflamm Bowel Dis. 2024 Apr 20:izae090. doi: 10.1093/ibd/izae090. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38642103

10

Smoking impacts outcomes in transcervical Zenker's diverticulectomy.

Kumar KD, Choudhry HS, Shah VP, Desai AD, Sibala DR, Patel AM, Patel P, Eloy JA. Kumar KD, et al. Among authors: desai ad. Am J Otolaryngol. 2024 Apr 16;45(4):104288. doi: 10.1016/j.amjoto.2024.104288. Online ahead of print. Am J Otolaryngol. 2024. PMID: 38640811

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,544 results

Search Page